Close

Alnylam Pharma (ALNY) Presents Updated Phase 1/2 OLE Results for Givosiran

November 9, 2018 8:02 AM EST Send to a Friend
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company presented updated results from the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login